甲胺增强抗瘤免疫力,改善预先切除胰腺癌的预后:一项观察性研究
Casper W F van Eijck1,2, Disha Vadgama2, Casper H J van Eijck1
1Department of Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Journal of the National Cancer Institute
|March 26, 2024
概括
在接受前期手术的胰腺癌患者中,甲福明的使用改善了生存率和改变了免疫特征. 它减少了亲瘤M2巨细胞和增加了抗瘤树突细胞,这表明它对免疫力产生了有利的影响.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢医学是一种代谢医学.
背景情况:
- 甲胺在瘤学中的作用需要对胰腺癌治疗进行研究.
- 这项研究探讨了甲福明对胰腺管腺癌 (PDAC) 存活率和免疫特征的影响.
研究的目的:
- 调查甲福明对胰腺癌患者存活率的影响.
- 为了在PDAC瘤中将甲福明的使用与独特的免疫特征相关联.
主要方法:
- 对PREOPANC随机对照试验 (RCT) 患者的分析.
- 包括前期切除和接受新辅助化学放射治疗 (nCRT) 的患者.
- 切除标本的转录组纳米弦免疫造型.
主要成果:
- 在前期切除的患者中,甲胺使用者表现出更好的生存率 (29 vs 14 个月中位数的生存率) 和5年生存率 (19% vs 5%).
- 在前期手术组中,甲胺使用是整体生存 (OS) 的有利预后因素.
- 甲胺使用者表现出瘤前驱M2巨细胞基因的表达不足以及瘤溶解树突细胞 (DC) 的水平升高.
结论:
- 在前期切除的胰腺癌患者中使用甲福明与改变的免疫特征和延长的存活率有关.
- 甲福明可能会降低瘤前的M2巨细胞活性,并增强抗瘤树突细胞功能.
- 这些免疫调节可能有助于改善胰腺癌的抗瘤免疫力.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
01:27Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K